S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$17.38
-3.4%
$15.49
$9.50
$18.85
$1.63B1.6854,322 shs1.11 million shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
MannKind Co. stock logo
MNKD
MannKind
$4.08
-0.5%
$4.28
$3.17
$5.75
$1.11B1.282.43 million shs1.29 million shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.90
+0.5%
$2.27
$1.86
$4.73
$21.80M1.0328,433 shs5,718 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-3.39%+8.90%+10.00%+16.02%+71.40%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
MannKind Co. stock logo
MNKD
MannKind
-0.49%-5.12%-12.63%+21.43%-7.27%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+0.53%-8.65%-17.03%-14.84%-48.51%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
3.1254 of 5 stars
4.52.00.00.03.21.70.6
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
2.0796 of 5 stars
3.50.00.00.01.40.81.9
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$22.5729.87% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
3.00
Buy$8.0096.08% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A

Current Analyst Ratings

Latest AVDL, LCI, MNKD, and TXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
3/15/2024
MannKind Co. stock logo
MNKD
MannKind
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.50
3/5/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
3/5/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.00
3/5/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.00
3/5/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $25.00
3/5/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
2/28/2024
MannKind Co. stock logo
MNKD
MannKind
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$10.00
2/28/2024
MannKind Co. stock logo
MNKD
MannKind
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.50
2/6/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$27.96M56.30N/AN/A$0.98 per share17.73
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
MannKind Co. stock logo
MNKD
MannKind
$198.96M5.55N/AN/A($0.91) per share-4.48
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.85N/AN/A$2.77 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$160.28M-$2.04N/A20.94N/AN/A-198.06%-84.51%5/2/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
MannKind Co. stock logo
MNKD
MannKind
-$11.94M-$0.05N/A25.50N/A-6.00%N/A-3.62%5/14/2024 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)

Latest AVDL, LCI, MNKD, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/4/2024Q4 2023
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million    
2/27/2024Q4 2023
MannKind Co. stock logo
MNKD
MannKind
-$0.01$0.01+$0.02$0.02$52.36 million$58.47 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/A
3.64
3.36
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
MannKind Co. stock logo
MNKD
MannKind
N/A
3.59
3.31
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
MannKind Co. stock logo
MNKD
MannKind
49.55%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
4.00%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
MannKind Co. stock logo
MNKD
MannKind
3.00%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
15490.58 million86.95 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
MannKind Co. stock logo
MNKD
MannKind
411270.68 million262.56 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable

AVDL, LCI, MNKD, and TXMD Headlines

SourceHeadline
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.comTherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com
americanbankingnews.com - April 19 at 2:14 AM
TherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosageTherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosage
pharmaceutical-technology.com - April 18 at 9:36 AM
StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)
americanbankingnews.com - April 13 at 2:18 AM
TherapeuticsMD Announces Full Year 2023 Financial ResultsTherapeuticsMD Announces Full Year 2023 Financial Results
businesswire.com - March 29 at 4:00 PM
TherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administrationTherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administration
pharmaceutical-technology.com - March 28 at 11:17 AM
25 Countries With Highest Abortion Rates25 Countries With Highest Abortion Rates
msn.com - March 12 at 3:55 PM
TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance
sg.finance.yahoo.com - March 10 at 1:13 PM
TherapeuticsMD Inc TXMDTherapeuticsMD Inc TXMD
morningstar.com - December 29 at 5:48 PM
Daily Markets: Today Brings Producer Prices, Retail Sales DataDaily Markets: Today Brings Producer Prices, Retail Sales Data
nasdaq.com - November 15 at 9:54 AM
TherapeuticsMD to Consider Strategic AlternativesTherapeuticsMD to Consider Strategic Alternatives
marketwatch.com - November 14 at 7:04 PM
TherapeuticsMD exploring strategic alternatives for companyTherapeuticsMD exploring strategic alternatives for company
msn.com - November 14 at 6:27 PM
TherapeuticsMD Announces Third Quarter 2023 Financial ResultsTherapeuticsMD Announces Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 6:27 PM
Boca Raton-based prescription service announces layoffs, says a third of workforce could be cutBoca Raton-based prescription service announces layoffs, says a third of workforce could be cut
bizjournals.com - October 4 at 5:11 PM
TherapeuticsMD Inc. stock falls Wednesday, underperforms marketTherapeuticsMD Inc. stock falls Wednesday, underperforms market
marketwatch.com - September 20 at 6:46 PM
TherapeuticsMD Inc. stock outperforms market despite losses on the dayTherapeuticsMD Inc. stock outperforms market despite losses on the day
marketwatch.com - August 15 at 7:00 PM
TherapeuticsMD Announces Second Quarter 2023 Financial ResultsTherapeuticsMD Announces Second Quarter 2023 Financial Results
finance.yahoo.com - August 14 at 7:50 AM
Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors
finance.yahoo.com - August 9 at 8:38 PM
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors
marketwatch.com - July 5 at 6:51 PM
TherapeuticsMD Rejected by FDA, Delay Could Be FatalTherapeuticsMD Rejected by FDA, Delay Could Be Fatal
thestreet.com - July 4 at 7:28 AM
TherapeuticsMD Inc. [TXMD] Investment Appeal on the RiseTherapeuticsMD Inc. [TXMD] Investment Appeal on the Rise
knoxdaily.com - June 19 at 3:12 PM
TherapeuticsMD: From Fallen And Forgotten To Cash CowTherapeuticsMD: From Fallen And Forgotten To Cash Cow
seekingalpha.com - May 23 at 9:28 AM
TherapeuticsMD Announces First Quarter 2023 Financial ResultsTherapeuticsMD Announces First Quarter 2023 Financial Results
finance.yahoo.com - May 15 at 4:19 PM
NeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.comNeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.com
news.google.com - May 14 at 10:42 AM
NeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybizNeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybiz
news.google.com - May 13 at 7:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avadel Pharmaceuticals logo

Avadel Pharmaceuticals

NASDAQ:AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
MannKind logo

MannKind

NASDAQ:MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.